ArticleBritish journal of cancer2017

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.

Alastair Greystoke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.